Home/Pipeline/F/TAF (High Dose Tablet) + F/TAF (Low Dose Tablet) + F/TAF (Lowest Dose Tablet) + F/TAF (High Dose TOS) + F/TAF (Low Dose TOS) + F/TAF (Lowest Dose TOS) + E/C/F/TAF + E/C/F/TAF (Low Dose) + Cobicistat (High Dose) + Cobicistat (Low Dose) + Cobicistat (TOS) + B/F/TAF (High Dose) + B/F/TAF (Low Dose) + B/F/TAF (High Dose TOS) + B/F/TAF (Low Dose TOS) + B/F/TAF (Lowest Dose TOS) + 3rd ARV Agent + Nucleos(t)ide reverse transcriptase inhibitors (NRTI) + ATV + DRV + Lopinavir Boosted with ritonavir (LPV/r)

ProductsF/TAF (High Dose Tablet) + F/TAF (Low Dose Tablet) + F/TAF (Lowest Dose Tablet) + F/TAF (High Dose TOS) + F/TAF (Low Dose TOS) + F/TAF (Lowest Dose TOS) + E/C/F/TAF + E/C/F/TAF (Low Dose) + Cobicistat (High Dose) + Cobicistat (Low Dose) + Cobicistat (TOS) + B/F/TAF (High Dose) + B/F/TAF (Low Dose) + B/F/TAF (High Dose TOS) + B/F/TAF (Low Dose TOS) + B/F/TAF (Lowest Dose TOS) + 3rd ARV Agent + Nucleos(t)ide reverse transcriptase inhibitors (NRTI) + ATV + DRV + Lopinavir Boosted with ritonavir (LPV/r)

F/TAF (High Dose Tablet) + F/TAF (Low Dose Tablet) + F/TAF (Lowest Dose Tablet) + F/TAF (High Dose TOS) + F/TAF (Low Dose TOS) + F/TAF (Lowest Dose TOS) + E/C/F/TAF + E/C/F/TAF (Low Dose) + Cobicistat (High Dose) + Cobicistat (Low Dose) + Cobicistat (TOS) + B/F/TAF (High Dose) + B/F/TAF (Low Dose) + B/F/TAF (High Dose TOS) + B/F/TAF (Low Dose TOS) + B/F/TAF (Lowest Dose TOS) + 3rd ARV Agent + Nucleos(t)ide reverse transcriptase inhibitors (NRTI) + ATV + DRV + Lopinavir Boosted with ritonavir (LPV/r)

ApprovedRecruiting

0 views this week 0 watching⚡ Active

Interest: 50/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

HIV-1-infection

Conditions

HIV-1-infection

Trial Timeline

Aug 27, 2024 → Mar 1, 2034

NCT ID

NCT06337032

About F/TAF (High Dose Tablet) + F/TAF (Low Dose Tablet) + F/TAF (Lowest Dose Tablet) + F/TAF (High Dose TOS) + F/TAF (Low Dose TOS) + F/TAF (Lowest Dose TOS) + E/C/F/TAF + E/C/F/TAF (Low Dose) + Cobicistat (High Dose) + Cobicistat (Low Dose) + Cobicistat (TOS) + B/F/TAF (High Dose) + B/F/TAF (Low Dose) + B/F/TAF (High Dose TOS) + B/F/TAF (Low Dose TOS) + B/F/TAF (Lowest Dose TOS) + 3rd ARV Agent + Nucleos(t)ide reverse transcriptase inhibitors (NRTI) + ATV + DRV + Lopinavir Boosted with ritonavir (LPV/r)

F/TAF (High Dose Tablet) + F/TAF (Low Dose Tablet) + F/TAF (Lowest Dose Tablet) + F/TAF (High Dose TOS) + F/TAF (Low Dose TOS) + F/TAF (Lowest Dose TOS) + E/C/F/TAF + E/C/F/TAF (Low Dose) + Cobicistat (High Dose) + Cobicistat (Low Dose) + Cobicistat (TOS) + B/F/TAF (High Dose) + B/F/TAF (Low Dose) + B/F/TAF (High Dose TOS) + B/F/TAF (Low Dose TOS) + B/F/TAF (Lowest Dose TOS) + 3rd ARV Agent + Nucleos(t)ide reverse transcriptase inhibitors (NRTI) + ATV + DRV + Lopinavir Boosted with ritonavir (LPV/r) is a approved stage product being developed by Gilead Sciences for HIV-1-infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06337032. Target conditions include HIV-1-infection.

What happened to similar drugs?

11 of 18 similar drugs in HIV-1-infection were approved

Approved (11) Terminated (3) Active (6)

✅B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboGilead SciencesApproved

✅B/F/TAFGilead SciencesApproved

✅Genvoya + Epclusa + BiktarvyGilead SciencesApproved

✅Switch to B/F/TAF + Continue current regimenGilead SciencesApproved

✅Maraviroc + TruvadaGilead SciencesApproved

✅B/F/TAF + TDF/3TC/EFVGilead SciencesApproved

✅Bictegravir/emtricitabine/tenofovir alafenamideGilead SciencesApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06337032	Approved	Recruiting	Aug 27, 2024	Mar 1, 2034	HIV-1-infection

Competing Products

20 competing products in HIV-1-infection

See all competitors

Product	Company	Stage	Hype Score
CVC 150 mg + CVC 300 mg	AbbVie	Phase 2	35
18F-Raltegravir	Merck	Phase 1	36
ISL/LEN + Antiretroviral Combinations	Merck	Phase 3	44
Delstrigo + KOCITAF	Merck	Phase 3	44
ISL/LEN + B/F/TAF + PTM B/F/TAF + PTM ISL/LEN	Merck	Phase 3	44
B/F/TAF + Atripla + B/F/TAF Placebo + Atripla Placebo	Gilead Sciences	Approved	35
GS-3242 + BVY + Standard of Care	Gilead Sciences	Phase 1	36
B/F/TAF	Gilead Sciences	Approved	43
Genvoya + Epclusa + Biktarvy	Gilead Sciences	Approved	39
GS-1720 + GS-4182 + Bictegravir/emtricitabine/tenofovir alafenamide + GS-1720/GS-4182 FDC + Placebo to Match BVY + Placebo to Match GS1720/GS-4182 FDC	Gilead Sciences	Phase 2/3	42
Dapivirine + Truvada	Gilead Sciences	Phase 2	27
Bictegravir/emtricitabine/tenofovir alafenamide	Gilead Sciences	Pre-clinical	22
GS-9131 + BIC + TAF + ARV regimen + DRV + RTV	Gilead Sciences	Phase 2	27
Bavtavirine + B/F/TAF + Standard of Care (Substudy 01) + GS-1720 + Standard of Care (Substudy 02) + GS-6212 + Standard of Care (Substudy 03)	Gilead Sciences	Phase 1	29
Truvada	Gilead Sciences	Phase 2	42
B/F/TAF	Gilead Sciences	Phase 1	29
Switch to B/F/TAF + Continue current regimen	Gilead Sciences	Approved	43
B/F/TAF + F/TAF + DTG + DTG Placebo + F/TAF Placebo + B/F/TAF Placebo	Gilead Sciences	Phase 3	40
GS-1720 + GS-4182 + Placebo to Match BVY + Bictegravir/emtricitabine/tenofovir alafenamide + GS-1720/GS-4182 FDC + Placebo to Match GS1720/GS-4182 FDC	Gilead Sciences	Phase 2/3	42
Vesatolimod + VRC07523LS + CAP256V2LS	Gilead Sciences	Phase 2	35